Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy
University of Pittsburgh
University of Pittsburgh
Merck Sharp & Dohme LLC
BeiGene
Ipsen
Nektar Therapeutics
MedImmune LLC
Novartis
AstraZeneca
Pfizer
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
AstraZeneca
AstraZeneca
UNC Lineberger Comprehensive Cancer Center
Pierre Fabre Medicament
Celgene
Amgen
Novartis
University of Pittsburgh
Groupe Oncologie Radiotherapie Tete et Cou
University of Miami
EMD Serono
SWOG Cancer Research Network